Affimed Therapeutics AG secured a first deal for its bispecific tandem diabody (Tandab) technology, with Johnson & Johnson. The agreement is being executed indirectly, through the financing of a single-asset subsidiary of Affimed, called Amphivena Therapeutics Inc., which has in-licensed an Affimed program.